Esmethadone
Esmethadone is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | 2 | 2 | 2 | 6 |
| Neuralgia | D009437 | EFO_0009430 | — | 2 | — | — | 1 | — | 3 |
| Heroin dependence | D006556 | EFO_0004240 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | 1 | 5 | — | 1 | 7 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 5 | — | 1 | 7 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | 5 | — | 1 | 7 |
| Pain | D010146 | EFO_0003843 | R52 | 2 | 1 | 1 | — | 1 | 4 |
| Postoperative pain | D010149 | — | G89.18 | — | — | 2 | — | — | 2 |
| Hernia | D006547 | HP_0100790 | K40-K46 | — | — | 1 | — | — | 1 |
| Morphine dependence | D009021 | EFO_0005612 | — | — | — | 1 | — | — | 1 |
| Opiate substitution treatment | D058850 | — | — | — | — | 1 | — | — | 1 |
| Scoliosis | D012600 | EFO_0004273 | M41 | — | — | 1 | — | — | 1 |
| Peripheral nervous system diseases | D010523 | HP_0009830 | G64 | — | 1 | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic pain | D059350 | HP_0012532 | — | 1 | 1 | — | — | 1 | 2 |
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | 1 | — | — | — | 1 |
| Psychomotor agitation | D011595 | — | — | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | 1 | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | 1 | 1 | — | — | — | 1 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Hepatitis c | D006526 | — | B19.2 | 1 | — | — | — | — | 1 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | — | 2 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | — | — | — | 1 | 1 |
| Intractable pain | D010148 | — | — | — | — | — | — | 1 | 1 |
| Hiv seropositivity | D006679 | — | — | — | — | — | — | 1 | 1 |
| Cocaine-related disorders | D019970 | — | F14 | — | — | — | — | 1 | 1 |
| Sleep wake disorders | D012893 | — | G47 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Esmethadone |
| INN | esmethadone |
| Description | Dextromethadone is a 6-(dimethylamino)-4,4-diphenylheptan-3-one that has (S)-configuration. It is the less active enantiomer of methadone and has very little activity on opioid receptors and mainly responsible for the inhibition of hERG K+ channels and thus for cardiac toxicity. The drug is currently under clinical development for the treatment of major depressive disorder. It has a role as a NMDA receptor antagonist and an opioid analgesic. It is an enantiomer of a levomethadone. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC(=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 5653-80-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL350719 |
| ChEBI ID | — |
| PubChem CID | 643985 |
| DrugBank | DB15198 |
| UNII ID | S95RZH8AMH (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 375 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use